November 4, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional ...
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. Findings from the Nordic–Baltic–British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease.
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers analysis to compare the safety and efficacy of biodegradable polymer stents (BP-DES) to the durable polymer Resolute Integrity drug-eluting stent (DP-DES) from Medtronic. At one year, patients with coronary artery disease who were treated with a biodegradable polymer stent showed no clinical benefits over patients treated with Resolute Integrity.
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early feasibility study, showing improved hemodynamics from baseline and consistent valve performance at one year. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, the positive new data from the first-of-its-kind early feasibility study led the U.S. Food and Drug Administration (FDA) to also recently approve the initiation of a Pivotal Investigational Device Exemption (IDE) study to evaluate the valve’s safety and effectiveness.
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the Amplatzer PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO). With the approval, patients in the United States with a PFO (a small opening between the upper chambers of the heart) who have suffered an ischemic stroke — a stroke resulting from blockages in the blood supply to the brain — will now have access to a closure device proven to reduce their risk of recurrent stroke, rather than relying on medical management alone.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Researchers at Stanford University have demonstrated for the first time the use of a dual optical and positron emission tomography (PET)/computed tomography (CT) activity-based probe to detect atherosclerotic plaques. The study is published in the October issue of The Journal of Nuclear Medicine.
November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the ...
Edwards Lifesciences Corp. announced new five-year hemodynamic data from the PARTNER Trial demonstrating excellent durability of the first-generation Edwards Sapien transcatheter heart valve (THV). This evaluation of 2,404 patients, encompassing 10,560 echoes and 6,493 patient years of follow-up, is the largest core lab based study of transcatheter heart valves to date.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Medtronic plc presented new positive data from two large registries aimed at evaluating 30-day clinical performance outcomes for the self-expanding, recapturable and repositionable CoreValve Evolut R System in “real-world” severe aortic stenosis patient populations at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting.
In an effort to improve patient care, Children's Hospital of Philadelphia's (CHOP) Information Services team is using data and advanced analytics to screen patients for venous thromboembolism (VTE). This innovative technology is being honored by Drexel University and CIO.com in their inaugural Analytics 50 award ceremony, which will be held on Nov. 9, 2016 at Drexel University's LeBow College of Business.
SecurityScorecard, a security rating and continuous risk monitoring platform, released its 2016 Healthcare Industry Cybersecurity Report in October. The report is a comprehensive analysis exposing alarming cybersecurity vulnerabilities across 700 healthcare organizations including medical treatment facilities, health insurance agencies and healthcare manufacturing companies. Security breaches in this industry pose devastating consequences, according to the company, because they can render an entire system or network inoperable, creating a life or death situation that needs immediate attention.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
At the 2016 annual meeting of the Radiological Society of North America (RSNA 2016), GE Healthcare will introduce the Revolution CT (computed tomography) scanner with Whisper Drive technology, designed to take high-speed scans that allow full imaging of the heart in just one heartbeat.
White coat hypertension, where patients have high blood pressure readings in a medical setting but normal blood pressure outside the doctor’s office, is most likely an innocuous condition that is not a predictor of heart disease or stroke — except in a small group of older patients. This conclusion was drawn from a study published recently in the Journal of the American College of Cardiology.
Micell Technologies Inc. announced that it presented five-year clinical safety and efficacy results from the DESSOLVE I and II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent). MiStent is designed to optimize vessel healing and long-term clinical performance in patients with coronary artery disease, and the presented data demonstrate sustained desirable clinical outcomes.